Aeon Biopharma Inc AEON Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

96,210

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,021

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Palmisano Robert J

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

96,210

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Palmisano Robert J

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,021

Price:

--
May 24, 2024 (filed on May 24, 2024)

Insider Name:

Sy Jennifer

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
May 24, 2024 (filed on May 24, 2024)

Insider Name:

Sy Jennifer

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Apr 12, 2024 (filed on Apr 16, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

10,000,000

Price:

--
Apr 11, 2024 (filed on Apr 12, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

10,000,000

Price:

--
Mar 24, 2024 (filed on Mar 26, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

5,000,000

Price:

--
Mar 19, 2024 (filed on Mar 21, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16,260

Price:

--

Filings by filing date

Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

96,210

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,021

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Palmisano Robert J

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

96,210

Price:

--
Aug 31, 2024 (filed on Sep 04, 2024)

Insider Name:

Palmisano Robert J

Ownership Type:

Direct Ownership

Securities:

Class A Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

36,021

Price:

--
May 24, 2024 (filed on May 24, 2024)

Insider Name:

Sy Jennifer

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
May 24, 2024 (filed on May 24, 2024)

Insider Name:

Sy Jennifer

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

Form 3 : Initial Statement of Beneficial Ownership of Securities

# or value acquired/disposed of:

--

Price:

--
Apr 12, 2024 (filed on Apr 16, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

10,000,000

Price:

--
Apr 11, 2024 (filed on Apr 12, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

10,000,000

Price:

--
Mar 24, 2024 (filed on Mar 26, 2024)

Insider Name:

Daewoong Co., Ltd

Ownership Type:

Indirect Ownership

Securities:

Senior Secured Convertible Note

Nature of Transaction:

J - Other transaction

# or value acquired/disposed of:

5,000,000

Price:

--
Mar 19, 2024 (filed on Mar 21, 2024)

Insider Name:

Thunen Shelley B

Ownership Type:

Direct Ownership

Securities:

Stock Option

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

16,260

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	5 Park Plaza, Suite 1750 IRVINE CA 92614
Tel:	N/A
Website:	https://aeonbiopharma.com
IR:	See website

Key People

Marc Forth President, Chief Executive Officer, Principal Financial Officer, Director	Alex Wilson Executive Vice President, Chief Legal Officer, Corporate Secretary	Jennifer Sy Principal Accounting Officer
Chad Oh Chief Medical Officer

Business Overview

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing its botulinum toxin complex, ABP-450 (prabotulinumtoxinA) injection or ABP-450, for debilitating medical conditions, with an initial focus on the neuroscience market. ABP-450 is a 2-chain polypeptide, a heavy chain joined by a bond to a light chain. ABP-450 interferes with nerve impulses by inhibiting the release of acetylcholine into the neuromuscular junction, causing a flaccid paralysis of muscles. The active biologic ingredient in ABP-450 is Clostridium botulinum toxin, type A with a complete molecular complex weight of 900 kDa. Its initial development programs for ABP-450 are directed at migraine, cervical dystonia, gastroparesis and post-traumatic stress disorder (PTSD). The Company has completed a Phase II study of ABP-450 for the treatment of cervical dystonia and are conducting a Phase II study of ABP-450 for the treatment of both chronic and episodic migraine.

Financial Overview

For the six months ended 30 June 2024, Aeon Biopharma Inc revenues was not reported. Net income totaled $46.1M vs. loss of $33M. Net income reflects Biotechnology & Medical Research segment income totaling $79.3M vs. loss of $27M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.89 to $1.06.

Employees:	5 as of Jun 30, 2024

Reporting Currency:	U.S. Dollars
Enterprise value:	$40.24M as of Jun 30, 2024
Annual revenue (TTM):	$0.00M as of Jun 30, 2024
EBITDA (TTM):	$106.35M as of Jun 30, 2024
Net annual income (TTM):	-$305.52M as of Jun 30, 2024
Free cash flow (TTM):	-$43.40M as of Jun 30, 2024
Net Debt Last Fiscal Year:	$9.85M as of Jun 30, 2024
Shares outstanding:	39,522,238 as of Aug 7, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization